Safety of intravitreal high-dose reinjections of triamcinolone acetonide.
OBJECTIVE
To report side effects after intravitreal high-dose reinjections of triamcinolone acetonide.


METHODS
Clinical interventional case series.


METHODS
Forty-six patients (47 eyes) received at least two intravitreal injections of approximately 20 to 25 mg triamcinolone acetonide for treatment of diabetic macular edema (n = 6 eyes), exudative age-related macular degeneration (n = 23), and other diseases. Intervals between injections were 6.7 +/- 3.4 months, 8.0 +/- 4.6 months, and 10.2 months, respectively, before the second (n = 47 eyes), third (n = 9), and fourth (n = 2) injection. Mean follow-up was 20.7 +/- 8.9 months.


RESULTS
After no reinjection were complications detected, other than those known to occur after a single intravitreal injection. After the first, second, and third injection, respectively, intraocular pressure remained normal in 24 (51%), 25 (53%), and 5 (56%) eyes.


CONCLUSIONS
Intravitreal high-dosage reinjections of triamcinolone acetonide may be tolerated within a mean follow-up of approximately 21 months.
Jonas
Jost B
JB
Department of Ophthalmology and Eye Hospital, Medical Faculty Mannheim of the Ruprecht-Karls-University Heidelberg, Germany. Jost.Jonas@ma.augen.uni-heidelberg.de
Degenring
Robert
R
Kreissig
Ingrid
I
Akkoyun
Imren
I
D005938:Glucocorticoids / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007429:Intraocular Pressure; D011446:Prospective Studies; D012164:Retinal Diseases / Q000188:drug therapy*; D012449:Safety; D013997:Time Factors; D014222:Triamcinolone Acetonide / Q000008:administration & dosage* / Q000009:adverse effects; D014822:Vitreous Body
D005938:Glucocorticoids; D014222:Triamcinolone Acetonide